Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance (Q36441487)

14 August 2017

1 reference

title

Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance (English)

1 reference

14 August 2017

0 references

1 reference

Michael J Doenhoff

1

0 references

author name string

Livia Pica-Mattoccia

series ordinal

2

1 reference

PubMed ID

16597202

14 August 2017

language of work or name

1 reference

1 April 2006

1 reference

Expert Review of Anti-infective Therapy

14 August 2017

1 reference

14 August 2017

4

1 reference

14 August 2017

2

1 reference

14 August 2017

199-210

1 reference

PubMed ID

16597202

on focus list of Wikimedia project

14 August 2017

ScienceSource

0 references

cites work

The global status of schistosomiasis and its control

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

The global epidemiological situation of schistosomiasis and new approaches to control and research

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Presentation and outcome of 1107 cases of schistosomiasis from Africa diagnosed in a non-endemic country

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

THE SUCCESSFUL USE OF ANTIMONY IN BILHARZIOSIS

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Antischistosomal drugs: past, present ... and future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Use of praziquantel for clinical treatment and morbidity control of schistosomiasis japonica in China: a review of 30 years' experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Schistosomiasis control: keep taking the tablets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Drugs for the control of parasitic diseases: current status and development in schistosomiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Resistance of Schistosoma mansoni to praziquantel: is there a problem?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Synthesis and properties of Praziquantel, a novel broad spectrum anthelmintic with excellent activity against Schistosomes and Cestodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Praziquantel, a new broad-spectrum antischistosomal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

21 January 2018

Schistosomiasis control

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Praziquantel and the control of schistosomiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Praziquantel--quality, dosages and markers of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Counterfeit praziquantel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Efficacy and side-effects of two praziquantel treatments against Schistosoma haematobium infection, among schoolchildren from Côte d'Ivoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Bioavailability of praziquantel increases with concomitant administration of food

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodes. An example of a complex study covering both tolerance and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Pharmacokinetics of praziquantel in healthy volunteers and patients with schistosomiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Schistosoma mansoni: chemotherapy of infections of different ages

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Effects of praziquantel on different developmental stages of Schistosoma mansoni in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Development of antischistosomal drugs in China, with particular consideration to praziquantel and the artemisinins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Effect of praziquantel on the immature stages of Schistosoma haematobium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Praziquantel: mechanisms of anti-schistosomal activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Characterisation of praziquantel metabolism by rat liver microsomes using cytochrome P450 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

International Commission for Protection Against Environmental Mutagens and Carcinogens. ICPEMC publication No. 18. Review of the genotoxicity and carcinogenicity of antischistosomal drugs; is there a case for a study of mutation epidemiology? Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Genotoxic activity of praziquantel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

New policies for using anthelmintics in high risk groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Praziquantel side effects and efficacy related to Schistosoma mansoni egg loads and morbidity in primary school children in north-east Ethiopia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

A benzodiazepine derivative and praziquantel: effects on musculature of Schistosoma mansoni and Schistosoma japonicum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Properties and drug sensitivity of adenosine triphosphatases from Schistosoma mansoni

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Light and electron microscopic studies on the effect of praziquantel on Schistosoma mansoni, Dicrocoelium dendriticum, and Fasciola hepatica (Trematoda) in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Schistosoma mansoni: Reduced efficacy of chemotherapy in infected T-cell-deprived mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Evidence for an immune-dependent action of praziquantel on Schistosoma mansoni in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Immunological involvement in the efficacy of praziquantel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Crystal structures of a schistosomal drug and vaccine target: glutathione S-transferase from Schistosoma japonica and its complex with the leading antischistosomal drug praziquantel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Are Ca2+ channels targets of praziquantel action?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Schistosome calcium channel beta subunits. Unusual modulatory effects and potential role in the action of the antischistosomal drug praziquantel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Creation by mutagenesis of a mammalian Ca(2+) channel beta subunit that confers praziquantel sensitivity to a mammalian Ca(2+) channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Specific sites in the Beta Interaction Domain of a schistosome Ca2+ channel beta subunit are key to its role in sensitivity to the anti-schistosomal drug praziquantel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Drug resistance in schistosomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Treatment and re-treatment strategies for schistosomiasis control in different epidemiological settings: a review of 10 years’ experiences

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Sustainable schistosomiasis control--the way forward

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

The USAID/Government of Egypt's Schistosomiasis Research Project (SRP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Immunology of human schistosomiasis: off the beaten path

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Vaccine-linked chemotherapy: can schistosomiasis control benefit from an integrated approach?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

New initiatives against Africa's worms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Towards control of schistosomiasis in sub-Saharan Africa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Progress towards countrywide control of schistosomiasis and soil-transmitted helminthiasis in Uganda

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

The efficacy of praziquantel against Schistosoma mansoni infection in Ndombo, northern Senegal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Schistosoma mansoni: maturation rate and drug susceptibility of different geographic isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

In vitro responses of praziquantel-resistant and -susceptible Schistosoma mansoni to praziquantel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Oxamniquine cures Schistosoma mansoni infection in a focus in which cure rates with praziquantel are unusually low.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Validation of sensitivity to praziquantel using Schistosoma mansoni worm muscle tension and Ca2+-uptake as possible in vitro correlates to in vivo ED50 determination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Determination of ED50 values for praziquantel in praziquantel-resistant and -susceptible Schistosoma mansoni isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Alterations in cytochrome-c oxidase expression between praziquantel-resistant and susceptible strains of Schistosoma mansoni.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Sequence and level of endogenous expression of calcium channel beta subunits in Schistosoma mansoni displaying different susceptibilities to praziquantel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Adult worm tegumental damage and egg-granulomas in praziquantel-resistant and -susceptible Schistosoma mansoni treated in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

An international initiative on praziquantel use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Efficacy of praziquantel against Schistosoma mansoni with particular consideration for intensity of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Current status of sensitivity to praziquantel in a focus of potential drug resistance in Egypt

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Stability and reproductive fitness of Schistosoma mansoni isolates with decreased sensitivity to praziquantel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

The impact of refugia on the development of thiabendazole resistance in Haemonchus contortus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Sustainable use of anthelmintics in grazing animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Efficacy and side effects of praziquantel treatment in a highly endemic Schistosoma mansoni focus at Lake Albert, Uganda

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Specific and sensitive diagnosis of schistosome infection: can it be done with antibodies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Is Schistosomicidal Chemotherapy Sub-curative? Implications for Drug Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Case report: Schistosoma mansoni infection: failure of standard treatment with praziquantel in a returned traveller

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

A double-blind field trial on the effects of artemether on Schistosoma japonicum infection in a highly endemic focus in southern China

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Comparative study of the effects of artemether and artesunate on juvenile and adult Schistosoma mansoni in experimentally infected mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Artemisinin-based combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

Worms can worsen malaria: towards a new means to roll back malaria?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

"Rapid-impact interventions": how a policy of integrated control for Africa's neglected tropical diseases could benefit the poor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.199

21 January 2018

Identifiers

DOI

10.1586/14787210.4.2.199

1 reference

14 August 2017

1 reference

PubMed ID

16597202